Results 161 to 170 of about 20,250 (180)

Dabrafenib and Trametinib Therapy for Advanced Anaplastic Thyroid Cancer – Real-World Outcomes From UK Centres

Clinical Oncology, 2023
K H Wong, L Wall, C Lorimer
exaly  

Trametinib potentiates TRAIL‐induced apoptosis via FBW7‐dependent Mcl‐1 degradation in colorectal cancer cells

Journal of Cellular and Molecular Medicine, 2020
Shijun Li
exaly  

Phase 2 Study of Dabrafenib Plus Trametinib in Patients With BRAF V600E-Mutant Metastatic NSCLC: Updated 5-Year Survival Rates and Genomic Analysis

Journal of Thoracic Oncology, 2022
Benjamin Besse, Fabrice Barlesi, Tae Min Kim   +2 more
exaly  

Trametinib

Reactions Weekly, 2015
openaire   +2 more sources

Trametinib in the treatment of multiple malignancies harboring MEK1 mutations

Cancer Treatment Reviews, 2019
Changying Li
exaly  

A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)

Annals of Oncology, 2015
Jun Hwee Kim, Julien Mazières, T De Pas   +2 more
exaly  

Dabrafenib/trametinib/trametinib

Reactions Weekly
openaire   +1 more source

Open-label, phase IIa study of dabrafenib plus trametinib in East Asian patients with advanced BRAF V600-mutant cutaneous melanoma

European Journal of Cancer, 2020
Sang Joon Shin, Tae Min Kim, Yun Fan
exaly  

Acneiform eruptions: A common cutaneous toxicity of the MEK inhibitor trametinib

Australasian Journal of Dermatology, 2014
Georgina V Long, Richard Kefford, Pablo Uribe   +2 more
exaly  

Dabrafenib and trametinib in BRAFV600E mutated glioma

CNS Oncology, 2017
Neil Kitchen, Paul Mulholland
exaly